Belite Bio, Inc (BLTE)
NASDAQ: BLTE · Real-Time Price · USD
157.28
+0.75 (0.48%)
Nov 11, 2026, 2:01 PM EST - Market open
Belite Bio Employees
Belite Bio had 41 employees as of December 31, 2025. The number of employees increased by 16 or 64.00% compared to the previous year. That makes Belite Bio the 35,806th largest employer in the world and 4,854th in the United States.
Employees
41
Change (1Y)
16
Growth (1Y)
64.00%
Revenue / Employee
n/a
Profits / Employee
-$2,496,683
Market Cap
6.33B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 41 | 16 | 64.00% |
| Dec 31, 2024 | 25 | 5 | 25.00% |
| Dec 31, 2023 | 20 | 4 | 25.00% |
| Dec 31, 2022 | 16 | 4 | 33.33% |
| Dec 31, 2021 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Ionis Pharmaceuticals | 1,480 |
| Axsome Therapeutics | 1,390 |
| Mirum Pharmaceuticals | 470 |
| Immunovant | 315 |
| Scholar Rock Holding | 289 |
| Cogent Biosciences | 258 |
| CG Oncology | 142 |
| Kodiak Sciences | 141 |
BLTE News
- 6 days ago - Belite Bio to Host Webcast on November 12, 2026, to Discuss Third Quarter 2026 Financial Results - GlobeNewsWire
- 13 days ago - Belite Bio price target lowered to $221 from $234 at Mizuho - TheFly
- 23 days ago - Belite Bio announces uplisting to Nasdaq Global Select Market - TheFly
- 23 days ago - Belite Bio Announces Uplisting to the Nasdaq Global Select Market - GlobeNewsWire
- 27 days ago - Belite Bio submits MAAs for tinlarebant in Singapore, UK and Switzerland - TheFly
- 27 days ago - Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1 - GlobeNewsWire
- 5 weeks ago - Belite Bio management to meet with Piper Sandler - TheFly
- 5 weeks ago - Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences - GlobeNewsWire